Skip to main content
Top
Published in: Surgery Today 11/2019

Open Access 01-11-2019 | Original Article

Is laparoscopic colorectal surgery with continuation of antiplatelet therapy safe without increasing bleeding complications?

Authors: Kazuhiro Taguchi, Manabu Shimomura, Hiroyuki Egi, Minoru Hattori, Shoichiro Mukai, Masatoshi Kochi, Haruki Sada, Yusuke Sumi, Ikki Nakashima, Shintaro Akabane, Koki Sato, Hideki Ohdan

Published in: Surgery Today | Issue 11/2019

Login to get access

Abstract

Purpose

The number of patients on antiplatelet therapy (APT) who need surgery is increasing; however, it is unclear whether APT should be continued for abdominal surgery, particularly laparoscopic colorectal surgery. We investigated the safety of continuing APT for patients undergoing laparoscopic colorectal surgery.

Methods

We collected retrospective data from 529 patients who underwent laparoscopic colorectal surgery at Hiroshima University between January, 2013 and December, 2018. We analyzed information related to APT. Thirty-six pairs were matched by the propensity score method between patients on APT (APT+) and those not on APT (APT−). We compared the surgical outcomes of both groups.

Results

Among 463 patients eligible for the study, 48 were on APT for cerebrovascular or cardiovascular disease, and 36 continued to take aspirin. In the case-matched comparison, the amount of intraoperative blood loss in the APT+ group was not significantly higher than that in the APT− group, and the incidences of bleeding complications, thromboembolic complications, and other complications were not significantly different between the groups.

Conclusion

In a case-matched comparison, continuation of aspirin during laparoscopic colorectal surgery did not increase perioperative complications. In laparoscopic colorectal surgery, continuation of aspirin is an acceptable strategy for patients with thromboembolic risk caused by interruption of APT.
Literature
1.
go back to reference Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62(7):1187–9.CrossRefPubMed Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004;62(7):1187–9.CrossRefPubMed
17.
go back to reference Shimomura M, Kochi M, Hinoi T, Egi H, Adachi T, Kobayashi T, et al. Clinical significance of pharmacological prophylaxis based on the original risk classification of venous thromboembolism after lower abdominal surgery. Hiroshima J Med Sci. 2016;65(3–4):53–9.PubMed Shimomura M, Kochi M, Hinoi T, Egi H, Adachi T, Kobayashi T, et al. Clinical significance of pharmacological prophylaxis based on the original risk classification of venous thromboembolism after lower abdominal surgery. Hiroshima J Med Sci. 2016;65(3–4):53–9.PubMed
19.
go back to reference Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 Suppl):132S–75S.CrossRefPubMed Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 Suppl):132S–75S.CrossRefPubMed
Metadata
Title
Is laparoscopic colorectal surgery with continuation of antiplatelet therapy safe without increasing bleeding complications?
Authors
Kazuhiro Taguchi
Manabu Shimomura
Hiroyuki Egi
Minoru Hattori
Shoichiro Mukai
Masatoshi Kochi
Haruki Sada
Yusuke Sumi
Ikki Nakashima
Shintaro Akabane
Koki Sato
Hideki Ohdan
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
Surgery Today / Issue 11/2019
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-019-01839-0

Other articles of this Issue 11/2019

Surgery Today 11/2019 Go to the issue